Navigation Links
SRI International Researchers Present Promising New Therapeutic for the Treatment of Multiple Myeloma
Date:5/11/2010

MENLO PARK, Calif., May 11 /PRNewswire/ -- SRI International, an independent nonprofit research and development organization, announced today that researchers have developed an anti-angiogenic molecule SR16388 that has demonstrated preclinical antitumor activity against multiple myeloma (MM). The new research was recently presented at the annual meeting of the American Association for Cancer Research (AACR), held in Washington, D.C.

Multiple myeloma is a cancer of the immune system that affects plasma cells in bone marrow. It is the second most common blood-based malignancy (after lymphoma), affecting approximately 20,000 new patients each year.

"More effective treatment options for multiple myeloma are urgently needed and the SRI cancer drug discovery team is actively working on developing next-generation agents that may extend the lives of patients and lead to a cure," said Lidia Sambucetti, Ph.D., senior director of SRI's Center for Cancer Research.

SR16388 has been shown to have excellent oral bioavailability and a favorable safety profile.  In studies, it has shown to potently inhibit angiogenesis in lung and prostate cancers. Based on in vitro and in vivo preclinical data, SRI researchers believe that SR16388 has promise as a new therapeutic for the treatment of multiple myeloma. In the new work presented at AACR, researchers demonstrated that SR16388 inhibits the growth of multiple myeloma cells and experimental tumors. This agent is different from current multiple myeloma therapies in that it works by blocking the ability of cancer cells to survive and grow in hypoxic (low oxygen level) microenvironments that are typical of this malignancy. In part, the drug does this by inhibiting the development of new blood vessels that supply oxygen and nutrients to multiplying cancer cells. SR16388 is currently in late-stage preclinical development, which will prepare the agent for entry into human clinical trials.

About SRI's Biosciences Division

SRI's Biosciences Division carries out basic research, drug discovery, and drug development, and provides contract services. SRI has all of the resources necessary to take R&D from idea to IND®—from initial discovery to the start of human clinical trials—and specializes in cancer, immunology and inflammation, infectious disease, and neuroscience. SRI's product pipeline has yielded marketed drugs, therapeutics currently in clinical trials, and additional programs in earlier stages. In its CRO business, SRI has helped government and other clients and partners advance well over 100 drugs into patient testing. SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.

About SRI International

Silicon Valley-based SRI International is one of the world's leading independent research and technology development organizations. SRI, which was founded by Stanford University as Stanford Research Institute in 1946 and became independent in 1970, has been meeting the strategic needs of clients and partners for more than 60 years. Perhaps best known for its invention of the computer mouse and interactive computing, SRI has also been responsible for major advances in networking and communications, robotics, drug discovery and development, advanced materials, atmospheric research, education research, economic development, national security, and more. The nonprofit institute performs sponsored research and development for government agencies, businesses, and foundations. SRI also licenses its technologies, forms strategic alliances, and creates spin-off companies. In 2009, SRI's consolidated revenues, including its wholly owned for-profit subsidiary, Sarnoff Corporation, were approximately $470 million.


'/>"/>
SOURCE SRI International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Medicomps Decipher Holter Monitor Provides Cardiac Reporting on the International Space Station
2. Novo Nordisk partners with international scientific community for Victoza(R) cardiovascular outcomes trial
3. Lexicon to Present at BIO International Convention
4. Phytomedics Inc. To Present at BIO 2010 International Convention
5. Systech International(R) Celebrates 25 Years of Innovating Packaging Technology Solutions
6. International Merchant Advisors to Develop Organic Science Branded Medical Marijuana Product Line
7. Winner Medical Participates in CMEF 2010, China International Medical Equipment Fair, in Shenzhen
8. International Merchant Advisors Completes All Stock Based Purchase of Medical Marijuana Company Organic Science, Inc.
9. Essilor Acquires FGX International, Becoming a Major Player in a New Fast-Growing Market
10. PricewaterhouseCoopers to Present First International Market Scorecard on Medical Technology Innovation at the 2010 International Medical Device Industry Compliance Congress
11. Bacterin International Introduces OsteoSelect(R) DBM Putty
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , December 2, 2016 bioLytical Laboratories, ein Weltführer ... bei den Mitgliedern des Apothekenbundes von Kenia eingeführt. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ...
(Date:12/2/2016)... , Dec. 2, 2016   CytoSorbents Corporation ... commercializing its European Union approved CytoSorb ® cytokine ... surgery patients worldwide, announced that Dr. Phillip Chan ... 9th Annual LD Micro Main Event investor conference ... at the Luxe Sunset Boulevard Hotel in ...
(Date:12/2/2016)... 1, 2016  Today, Simpson Healthcare Executives, a global ... being selected as winners of multiple awards at the ... at the PLATINUM level, Blue Zones Menu at the ... GOLD Level, and our proprietary 3ConneX Platform at the ... Executives, we are excited to showcase our new Platinum ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... , ... Center for Autism and Related Disorders (CARD) Portland today announced plans ... (ASD) and other developmental disabilities. The group, which is being launched with the help ... opportunity to share stories and advice, seek help, and continue their education on how ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than half of American teens report ... parents report speaking with their child about sex related topics, less than 60 percent ... is proud to announce the launch of its second edition of the “Sexual Wellness” ...
(Date:12/2/2016)... ... 02, 2016 , ... The PAINWeekEnd Regional Conference will be ... in Honolulu, offering local frontline clinicians the opportunity to extend their certified continuing ... for supplemental training related to pain management has surged dramatically in recent years, ...
(Date:12/2/2016)... ... December 02, 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), ... night. No other wearable health technology on the market can deliver all that rejiva ... more meaningful insights about their health than the usual heart rate and steps taken”, ...
Breaking Medicine News(10 mins):